Clinical trials of intensive versus less intensive control of hypertension: HOPE or HYPE?
Publication
, Journal Article
Wyatt, CM; Chertow, GM
Published in: Kidney Int
September 2016
The recently published Heart Outcomes Prevention Evaluation trial (HOPE-3) demonstrated no benefit of lowering blood pressure with candesartan and hydrochlorothiazide in persons at intermediate cardiovascular risk and with adequate blood pressure control as determined by the enrolling physician. The results of Systolic Blood Pressure Intervention Trial (SPRINT) and HOPE-3 highlight the importance of considering differences in study design and patient population when interpreting the results of clinical trials.
Duke Scholars
Published In
Kidney Int
DOI
EISSN
1523-1755
Publication Date
September 2016
Volume
90
Issue
3
Start / End Page
460 / 462
Location
United States
Related Subject Headings
- Urology & Nephrology
- Risk Factors
- Hypertension
- Hydrochlorothiazide
- Humans
- Cardiovascular Diseases
- Blood Pressure
- Antihypertensive Agents
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Wyatt, C. M., & Chertow, G. M. (2016). Clinical trials of intensive versus less intensive control of hypertension: HOPE or HYPE? Kidney Int, 90(3), 460–462. https://doi.org/10.1016/j.kint.2016.06.021
Wyatt, Christina M., and Glenn M. Chertow. “Clinical trials of intensive versus less intensive control of hypertension: HOPE or HYPE?” Kidney Int 90, no. 3 (September 2016): 460–62. https://doi.org/10.1016/j.kint.2016.06.021.
Wyatt CM, Chertow GM. Clinical trials of intensive versus less intensive control of hypertension: HOPE or HYPE? Kidney Int. 2016 Sep;90(3):460–2.
Wyatt, Christina M., and Glenn M. Chertow. “Clinical trials of intensive versus less intensive control of hypertension: HOPE or HYPE?” Kidney Int, vol. 90, no. 3, Sept. 2016, pp. 460–62. Pubmed, doi:10.1016/j.kint.2016.06.021.
Wyatt CM, Chertow GM. Clinical trials of intensive versus less intensive control of hypertension: HOPE or HYPE? Kidney Int. 2016 Sep;90(3):460–462.
Published In
Kidney Int
DOI
EISSN
1523-1755
Publication Date
September 2016
Volume
90
Issue
3
Start / End Page
460 / 462
Location
United States
Related Subject Headings
- Urology & Nephrology
- Risk Factors
- Hypertension
- Hydrochlorothiazide
- Humans
- Cardiovascular Diseases
- Blood Pressure
- Antihypertensive Agents
- 3202 Clinical sciences
- 1103 Clinical Sciences